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Abstract
Acute viral infections pose many practical challenges for the accurate assessment of the
impact of novel therapies on viral growth and decay. Using the example of influenza A, we
illustrate how the measurement of infection-related quantities that determine the dynamics
of viral load within the human host, can inform investigators on the course and severity of
infection and the efficacy of a novel treatment. We estimated the values of key infection-
related quantities that determine the course of natural infection from viral load data, using
Markov Chain Monte Carlo methods. The data were placebo group viral load measure-
ments collected during volunteer challenge studies, conducted by Roche, as part of the
oseltamivir trials. We calculated the values of the quantities for each patient and the correla-
tions between the quantities, symptom severity and body temperature. The greatest varia-
tion among individuals occurred in the viral load peak and area under the viral load curve.
Total symptom severity correlated positively with the basic reproductive number. The most
sensitive endpoint for therapeutic trials with the goal to cure patients is the duration of infec-
tion. We suggest laboratory experiments to obtain more precise estimates of virological
quantities that can supplement clinical endpoint measurements.
Introduction
According to a 2014 report, the costs of developing a new pharmaceutical has increased by
145% since 2003[1]. A major part of this cost increase is due to losses incurred on drug candi-
dates that fail during clinical development[2]. Failure may be due to adverse events or an
inability to detect beneficial effects on the target disease. The reasons why clinical trials fail to
demonstrate efficacy of potential novel treatments are many and complex. Failure is often due
to the choice of inadequate endpoints, or poor trial design. Good endpoints in clinical trials
should fulfill the following two key criteria: i) they should reflect the action of the treatment on
the underlying cause of disease, and ii) they should be reliably quantifiable.
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Acute viral infections pose particular challenges for any assessment of the impact of novel
therapies. They typically have a short incubation period (a few days) and rapid onset of clinical
symptoms. Consequently, patients usually present at clinics after the viral load peak has passed
and the infection is already in the decline phase. Only a few measurements of viral load or
symptoms can be taken before the infection terminates due to the immunological response of
the human host. Using the example of influenza A, we discuss how a quantitative analysis of
viral population growth within the patient can help investigators to define more reliable end-
points and improve the assessment of the efficacy of potential novel treatments.
Symptom scores, although typically required by regulatory agencies as clinical endpoints,
are seldom reliably quantifiable and often do not reflect the action of treatment on the patho-
genic agent. For example, symptoms may be measured by asking patients how they are feeling,
and therefore are at risk of being subjective and at best semi-quantitative[3]. Moreover, symp-
toms may not accurately reflect the pathologic process targeted by a specific treatment. In the
case of influenza A, respiratory and systemic symptoms are not only caused by viral tissue
damage, but also by the immune response to the viral infection itself. In severely ill patients
with multiple morbidity-inducing conditions, symptom scores may not give any indication of
the successful action of a treatment. Influenza treatment may clear the viral infection, but
symptoms may persist due to secondary bacterial pneumonia[4].
The most suitable endpoints that best reflect the effect of a treatment on acute viral infec-
tions should be related to viral load. We chose influenza A as an example, because the recent
controversy about the efficacy of established antiviral treatments against influenza A has reig-
nited interest in improved endpoint measurements for the assessment of antiviral treatments
and suitable statistical techniques to compare them across groups[5–8]. Since several pharma-
ceutical companies are working on novel treatments against influenza A including immuno-
therapeutic approaches[9], our analysis can inform future trials of potential new influenza
treatments. The models are most useful for the planning of phase I studies, but more general
conclusions can also be drawn for phase II and III studies.
Materials and Methods
In prior research we have analysed the properties of a simple differential equation model of
viral load dynamics in influenza A infection and a number of measurable infection-related
quantities which can be derived from this model (Fig 1)[10]. The model has been developed
from a standard model [11], by assuming that the viral dynamics are much faster than those of
infected cells. As we do not have quantitative information on the dynamics of infected cells,
this is a sensible assumption that allows us to reduce the number of unknown parameters in
the system. The model is general enough to be applicable to other acute viral infections. The
analytical properties of this model and the derivation of the infection-related quantities have
been discussed elsewhere [10]. In brief, the dynamics of the model are given by the following
equations:
dT
dt
¼ bTV
dV
dt
¼ rbTV  gV
where T is the number of epithelial target cells susceptible to viral infection, V is the viral load
(measured in TCID50/ml), β is the infection rate of target cells, r is the virus production rate,
and γ is the virus death or clearance rate which encompasses the action of speciﬁc and non-
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speciﬁc immune mechanisms. The infection-related quantities that can be derived from this
model and their interpretations are listed in Table 1. The analytical expressions of the quanti-
ties are given in S1 Table (details in [10]).
We fitted the model to viral load data of nine patients from the placebo groups of volunteer
challenge studies conducted by Roche as part of the original Oseltamivir trials, using Markov
Chain Monte Carlo (MCMC) methods [12]. All volunteers were screened for HI titre to
Fig 1. Schematic illustration of key infection-related quantities that define the course of acute viral infections. Black line: viral load
curve over time. Filled area indicates viral load area under the curve (AUC). X-axis: time in days post infection. Y-axis: log10 viral load (TCID50/
ml).
doi:10.1371/journal.pone.0158237.g001
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exclude pre-existing immunity against the challenge strain. We estimated the parameter values
for each patient. See S1 File for a more detailed description of the data and fitting procedure.
We used the parameter estimates to determine the infection-related quantities for each patient.
We assessed the variability of the quantities among patients by calculating the coefficients of
variation (CV).
In addition to viral load measurements, the data also included temperature measurements
and total symptom scores (Jackson score [13]) for each patient at different time points. We cal-
culated pairwise correlations (Pearson’s r) between individual viral load and temperature mea-
surements over time, and between individual viral load and symptom score measurements
over time. We also calculated pairwise correlations between each of the nine infection-related
quantities, and between the infection-related quantities and the area under the curve (AUC) of
the total symptom scores and the temperature area under the curves. The latter two quantities
measure the total symptom severity and temperature increase over the entire course of infec-
tion (the total symptom score AUC is the AUC over all Jackson scores at each measured time
point). We determined the statistical significance of the correlations with two different correc-
tion methods for multiple comparison (11 comparisons in total), the Bonferroni method and
the Benjamini-Hochberg method [14].
Written informed consent was obtained from each participant in a form approved by the
institutional review boards of the University of Virginia, Charlottesville, and the University of
Rochester, Rochester, NY, and subjects were compensated for participation. The review board
of the named institution has approved the study in which the data we used was collected.
Results
Fig 2 shows the model fits for nine patients. The parameter estimates are shown in S2 Table.
Compared to the 95% credible intervals of individual parameter estimates, the variation among
patients in the infection-related quantities shown in Table 2 is relatively small. This is not sur-
prising considering that the volunteers in the original challenge study were all young, healthy
adults from a narrow age band (18–27 years). The greatest variation among individuals occurs
in peak viral load (CV = 1.26) and viral load area under the curve (AUC) (CV = 1.19) (see S3
Table for all coefficients of variation.) Temperature significantly correlates with viral load
Table 1. Infection-related quantities derived from a simple viral dynamics model that can improve the assessment of therapy against acute viral
diseases[10].
Infection-related
quantity
Interpretation Practical use
Basic reproductive ratio
(R0)
Mean number of cells infected by one primary infected cell. If
R0>1 the infection will establish in the patient.
Determine if treatment can stop infection (bring R0 below 1)
Area under the viral load
curve (AUC)
Total amount of virus shed over the time of infection; indicates
infectiousness and severity of infection.
Determine if treatment reduces infectiousness and severity
of infection
Initial viral growth rate Rate at which virus multiplies in the early stage of the infection Determine if (prophylactic) treatment reduces viral growth
Late viral decay rate Rate at which virus is cleared towards the end of the infection Determine if treatment increases rate of late viral decay
Peak viral load Maximum viral load; indicates severity of infection Determine by how much treatment reduces viral load peak
Time to peak viral load Time required to reach peak viral load N/A
Duration of infection Time from onset of infection to full clearance; in practice
measured as time from onset to viral load fall under detection
limit
Distinguishes short-lived from chronic infections; determine
by how much treatment shortens duration of infection
Generation time Speed at which infection spreads in population Determine if treatment slows down speed at which infection
spreads
Fraction of dead cells at
end of infection
Indicates tissue damage caused by infection; measure of
severity of infection
Determine if treatment reduces tissue damage
doi:10.1371/journal.pone.0158237.t001
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(r = 0.328, p = 0.0025). Total symptom scores also correlate with viral load (r = 0.233,
p = 0.03385). When we determined the correlations between infection-related quantities using
the Bonferroni correction, the following correlations were significant: R0 and the duration of
infection (r = 0.947, pbonferroni = 5.902x10
-3), viral load AUC and peak viral load (r = 0.9994,
pbonferroni = 7.068x10
-10), viral load AUC and late viral decay rate (r = 0.9509, pbonferroni =
4.514x10-3), time to peak viral load and generation time (r = 0.9644, pbonferroni = 1.487x10
-3),
time to peak viral load and initial viral growth rate (r = -0.9459, pbonferroni = 3.384x10
-3), and
Fig 2. Model fit to data for nine patients. Black dots: viral load data points. Red line: model fit based on median estimates. Light brown area:
sample from posterior distributions of viral dynamics. Patients 2 and 3 have a missing data point at day 1. Accordingly, there is great
uncertainty about the time of the viral load peak, as illustrated by the sample from the posterior distribution.
doi:10.1371/journal.pone.0158237.g002
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peak viral load and late viral decay rate (r = 0.9601, pbonferroni = 2.212x10
-3). It should be noted
that the infection-related quantities are related to each other via the model parameters, which
explains the very high correlations.
When we used the Benjamini-Hochberg correction, three additional correlations were sig-
nificant: R0 and total symptom score AUC (r = 0.8613, pBH = 7.374x10
-4), fraction of dead cells
at the end of infection and duration of infection (r = 0.8025, pBH = 0.01961), generation time
and initial viral growth rate (r = -0.8693, pBH = 0.01834). Here R0 and total symptom score
AUC are independent, whereas the fraction of dead cells and the duration of infection, as well
as the generation time and initial viral growth rate are dependent on each other via the viral
dynamics model. See Table 3 for all correlations.
Even though the association is not statistically significant, we observe that Patients 3, 4 and
5 have the highest fraction of dead cells and also the highest symptom scores AUC (Table 2,
Fig 3).
Discussion
Our parameter estimates are of the same size as previous estimates from studies using compa-
rable models (for example [11]). As the parameters in these models tend to be highly corre-
lated, the uncertainty around individual parameter estimates is generally large. Our analysis is
limited by the small sample size which, however, is not unusual in studies fitting viral dynamics
models.
Our estimates of the basic reproductive number (R0) tend to be lower than previously
reported results [11,15]. Some of these published estimates were derived from tissue culture
experiments, where, in the absence of any immune response, R0 is likely to be higher. The viral
strains used also differed in the various studies (influenza A Texas/36/91 (H1N1) in our study,
Hong Kong/123/77 (H1N1) in [11], and Albany/1/98 (H3N2) in [15]). As some viral strains
may disseminate faster through infected tissue than others, infection by such strains may be
associated with higher R0 values. Moreover, some of the earlier studies consider a latent
Table 2. Values of infection-related quantities of nine patients based onmedian estimates of parameters and 95% credible intervals.
Patient number #1 #2 #3 #4 #5 #6 #7 #8 #9
Basic reproductive
ratio (R0)
2.33[1.279,
4.026]
4.00[2.497,
15.29]
5.52[2.451,
43.76]
9.60[5.309,
21.85]
6.00[4.170,
8.987]
2.10[1.079,
6.483]
2.78[1.840,
4.092]
1.63[1.240,
2.428]
4.36[2.717,
7.321]
Area under the viral
load curve (AUC)
79665
[19394,
367729]
67364
[18814,
262194]
5892[1838,
22013]
4111[1652,
11934]
14966
[4760,
50487]
3448[1173,
27139]
42101
[11496,
157812]
208096
[47773,
940812]
65845
[18951,
241242]
Initial viral growth
rate
7.39[5.588,
9.406]
8.17[6.158,
23.36]
7.06[4.674,
31.17]
8.24[5.627,
11.87]
8.87[6.764,
11.40]
3.12[2.116,
3.417]
7.38[5.756,
9.193]
7.76[6.419,
9.267]
8.18[6.178,
10.63]
Late viral decay rate 5.59[2.745,
21.68]
2.73[1.549,
4.561]
1.53[0.630,
3.614]
0.97[0.486,
1.569]
1.78[1.216,
2.444]
2.15[2.124,
4.976]
4.18[2.649,
7.410]
12.34[5.915,
29.56]
2.44[2.432,
2.453]
Peak viral load 94472
[20448,
438369]
74352
[17677,
339935]
4592[1112,
22092]
2535[816,
9361]
14175
[3817,
54851]
1507[489,
7210]
49530
[11883,
206486]
250118
[54944,
1154068]
70852
[69555,
71654]
Time to peak viral
load (days)
2.18[1.907,
2.488]
2.02[0.778,
2.337]
2.03[0.449,
2.531]
1.73[1.305,
2.140]
1.77[1.500,
2.023]
3.28[2.541,
3.774]
2.15[1.918,
2.384]
2.29[2.112,
2.449]
2.00[1.984,
2.010]
Duration of
infection
4.69[3.561,
5.655]
5.84[5.126,
7.339]
6.39[4.799,
10.93]
8.15[6.321,
13.03]
6.29[5.469,
7.685]
5.56[3.807,
9.863]
4.95[4.443,
5.571]
4.04[3.288,
4.665]
6.16[5.344,
7.773]
Generation time
(days)
2.55[2.008,
3.676]
2.09[0.784,
2.641]
2.07[0.463,
4.016]
1.73[1.327,
2.168]
1.78[1.502,
2.066]
4.02[2.573,
6.050]
2.40[2.004,
2.994]
3.09[2.488,
3.669]
2.05[1.688,
2.555]
Fraction of dead
cells at end of
infection
0.919
[0.7779,
0.9833]
0.983
[0.9305,
1.0000]
0.996
[0.9275,
1.0000]
1.000
[0.9952,
1.0000]
0.998
[0.9855,
0.9999]
0.9000.7289,
0.9985]
0.946
[0.8718,
0.9843]
0.843
[0.7692,
0.9259]
0.988
[0.9433,
0.9993]
doi:10.1371/journal.pone.0158237.t002
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infection stage which can increase estimates of R0. We did not consider a latent stage, as the
data did not contain enough information to justify additional parameters.
In our analysis, peak viral load and viral load AUC are the most variable infection-related
quantities. They were also strongly correlated, indicating that viral load AUC is mainly deter-
mined by peak viral load. High variability in AUC is thought to reflect high variability in infec-
tiousness among individuals.
Table 3. Pairwise correlations between infection-related quantities, between infection-related quantities and temperature area under the curve,
and between infection-related quantities and symptom score area under the curve. Correlations that are significant using the Bonferroni correction for
multiple comparisons are indicated by an asterisk. Correlations that are significant using the less stringent Benjamini-Hochberg correction are indicated by a
diamond. Values below the diagonal show Pearson’s correlation coefficient, values above the diagonal show uncorrected p-values for each correlation.
AUCS: total symptom score area under the curve. AUCT: temperature area under the curve. R0: basic reproductive number. AUCV: viral load area under the
curve. FDC: fraction of dead cells at end of infection. tpeak: time to peak viral load. Vpeak: peak viral load. tg: generation time. IGR: initial viral growth rate. LDR:
late viral decay rate. D: duration of infection.
AUCS AUCT R0 AUCV FDC tpeak Vpeak tg IGR LDR D
AUCS 0.103 2.85E-3 ^ 0.151 0.183 0.216 0.163 0.186 0.497 0.227 0.0170
AUCT 0.5782 0.143 0.0747 0.251 0.957 0.0739 0.734 0.840 0.0993 0.0903
R0 0.8613 ^ 0.5287 0.121 0.0145 0.0627 0.119 0.0282 0.238 0.0725 1.07E-4 ^ *
AUCV -0.5203 -0.6204 -0.5544 0.0312 0.973 1.28E-11 ^ * 0.524 0.536 8.21E-5 ^ * 0.0333
FDC 0.4876 0.4275 0.7735 -0.7126 0.0678 0.0266 7.88E-3 0.232 0.0116 9.24E-3 ^
tpeak -0.4576 -0.0214 -0.6413 0.0135 -0.6321 0.958 2.70E-5 ^ * 6.15E-5 ^ * 0.696 0.254
Vpeak -0.5081 -0.6216 -0.5572 0.9994^ * -0.7266 0.0209 0.506 0.554 4.02E-5 ^ * 0.0309
tg -0.4844 -0.1324 -0.7215 0.2457 -0.8118 0.9644 ^ * 0.2563 2.33E-3 ^ 0.289 0.109
IGR 0.2616 -0.0790 0.4382 0.2389 0.4436 -0.9549 ^ * 0.2289 -0.8693^ 0.845 0.604
LDR -0.4474 -0.5832 -0.6240 0.9509^ * -0.7886 0.1524 0.9601 ^ * 0.3981 0.0766 0.0116
D 0.7620 0.5960 0.9470^ * -0.7067 0.8025 ^ -0.4256 -0.7135 -0.5708 0.2011 -0.7886
doi:10.1371/journal.pone.0158237.t003
Fig 3. Viral load curves, temperature curves and total symptom score curves of nine patients.
doi:10.1371/journal.pone.0158237.g003
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We found that viral load correlates significantly with body temperature and total symptom
scores, but the correlations were not very strong. This may indicate that, although viral load is
ultimately responsible for infection-related illness, other processes, for example the immune
response, cause symptoms. Alternatively, the reporting of symptoms may be rather subjective
and therefore difficult to quantify accurately.
We found that R0 has a significant positive correlation with the duration of infection and
the total symptom score AUC. Consequently, R0 may be interpreted as an indicator for disease
severity.
Viral load AUC positively correlates with peak viral load and with the late viral decay rate.
Peak viral load correlates positively with the late viral decay rate. This suggests that infections
with a high peak viral load tend to decline rapidly after the peak (intense, but short infection),
whereas infections with a low peak viral load tend to decline more slowly (mild, but extended
infection).
The fraction of dead cells at the end of infection correlates positively with the infection
duration. This means that, according to our model, longer infections cause more severe tissue
damage. In addition, we observed that the patients with the highest fraction of dead cells at the
end of infection have the greatest total symptom score AUCs. A possible interpretation may be
that symptoms are at least partly caused by tissue damage. The inter-individual variability in
the fraction of dead cells, however, is very low (CV = 0.05788, see S3 Table).
Both time to peak viral load and generation time were negatively correlated with initial viral
growth. This means that an infection caused by slowly reproducing virus spreads more slowly
and has a later peak than an infection caused by faster reproducing virus.
With a bigger sample size, more correlations between infection-related quantities may be
found to be significant. For example, in coronavirus infection, a shorter incubation time is
associated with more severe disease [16].
Clinical researchers conducting trials of candidate therapies for acute viral infections should
be most interested in how infection-related measures change upon treatment. In Figs 4 and 5
we show schematically what changes to expect in different infection-related quantities follow-
ing treatment, (for a thorough sensitivity analysis see [10]).
We consider treatments that act on the infection rate (in the case of influenza A, for exam-
ple, amantadines [17]), the viral production rate (neuraminidase inhibitors against influenza A
[18]), and the viral clearance rate (monoclonal antibodies against influenza A are thought to
act in this way [19]). We consider treatments that are given on days 1, 2 and 3 post infection.
As we derived in [10], treatments that act on viral growth parameters (infection rate and
viral production rate) are most effective, when they are given before the time of peak viral load
(day 1). They can greatly reduce peak viral load, shorten the duration of infection and reduce
the viral load AUC (Fig 4A and 4B). In contrast, after the peak (days 2 and 3), a small to negli-
gible effect on the duration of infection and the viral load AUC is observed (Fig 5A, 5B, 5D and
5E). Our results agree with those from a similar analysis by Kamal et al. [20].
Since patients with acute viral infections typically present at clinics after the time of peak
viral load, our model suggests that it will be difficult to detect the impact of a treatment that
acts on the infection rate or viral production rate. This may be one of the reasons why different
studies have shown ambiguous results on the efficacy of neuraminidase inhibitors for the treat-
ment of influenza A [5–7].
According to our model, when treatments that act on the virus clearance rate are given
before the time of peak viral load, they can slow down viral growth and reduce the viral load
peak and AUC (Fig 4C). Shortly after the peak, their impact on viral decay and infection dura-
tion could be much stronger than that of treatments acting on viral growth parameters (Fig 5C
and 5F).
Measuring the Impact of Novel Therapies for Acute Viral Infections
PLOS ONE | DOI:10.1371/journal.pone.0158237 July 1, 2016 8 / 13
Our predictions strongly depend on the assumption that the infection is target-cell-limited.
In infections that are not target-cell-limited and where immunity plays a greater role in reduc-
ing viral load, treatments acting on viral growth parameters are expected to have a much stron-
ger effect after the viral load peak.
The choice of endpoint in a clinical trial depends in part on the therapeutic goal. If the goal
is to reduce transmission of an infectious agent, the viral load AUC, a measure of infectious-
ness, is a sensible endpoint. If the goal is to clear infection in a patient, other endpoints may be
more useful. Based on our analyses, we make the following recommendations on clinical proto-
cols for the assessment of treatments for acute viral infections with the goal to clear infection in
a patient. Our general conclusions hold for all trial phases, but some of our suggestions con-
cerning practical implementation may only be applicable in phase I studies.
When a treatment is given before the time of peak viral load the viral load AUC is com-
monly used as a virological endpoint. One of the reasons for this is that the AUC is affected by
the peak viral load and the duration of infection, and therefore contains more information
about the course of infection than either of these quantities on their own. Consequently, the
viral load AUC should be the most sensitive indicator of the efficacy of a treatment.
According to our findings, however, the viral load AUC is the infection-related quantity
that varies most among individuals. Due to the high natural variability among untreated
patients, it should be more difficult to detect a statistically significant difference between
treated and control groups. The same consideration holds for the peak viral load which is also
highly variable. Conversely, the duration of infection varies much less among individuals
(CV = 0.2059). Therefore, besides the reduction in AUC and peak viral load, the duration of
infection should be considered as an endpoint.
When a treatment is given after the peak viral load, the AUC is not a very sensitive marker
of impact, because the reduction in the total area will be relatively smaller (see Fig 5). The
increase in the late viral decay rate and the shortening of the infection duration should be used
Fig 4. Schematic illustration of changes expected in key infection-related quantities in treated versus untreated individuals (treated
before time of peak viral load on day 1). Treatments acting on the infection rate or viral production rate have a strong impact on infection, if given
before the time of peak viral load (a, b). They reduce peak viral load, duration of infection and viral load area under the curve (AUC). Treatments
acting on virus clearance have a weaker effect on the course of infection, if given before the time of peak viral load (c). Black line: viral load curve
in untreated infection. Red line: viral load curve in treated infection. Fill indicates viral load area under the curve in treated infection.
doi:10.1371/journal.pone.0158237.g004
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as alternative endpoints. The duration of infection should be a more sensitive efficacy measure
compared to the increase in the late viral decay rate, because the latter is more variable among
individuals (CV = 0.9402).
The measured duration of infection will depend on the number of measurements taken and
the sensitivity of the viral load assay. It is also easy to miss the peak viral load, if the measure-
ment intervals are spaced too far apart. This will affect the estimate of the viral load AUC. We
recommend taking at least two to three measurements per day, if possible (mainly in phase I
studies). This is partly because the reduction in infection duration in treated individuals is typi-
cally not more than one day (Fig 5). If only one measurement per day is taken, it will be diffi-
cult to resolve the differences in infection duration between treated and untreated groups. The
same rationale holds for measuring the viral decay rate.
Taking more frequent viral load measurements is essential for fitting mechanistic models of
acute viral infections to data. In order to fit the model we introduced above, one needs a mini-
mum of at least five data points taken at different times [21]. In particular, parameter estima-
tion requires early data points before the time of the peak. Such data can normally only be
Fig 5. Schematic illustration of changes expected in key infection-related quantities in treated versus untreated individuals (treated
after time of peak viral load–days 2, 3). After the peak treatments acting on the infection rate or virus production rate have a small to negligible
effect on infection-related quantities (a, b, d, e). After the peak treatments acting on the virus clearance rate have a bigger impact on infection-
related quantities (c, f). Black line: viral load curve in untreated infection. Red line: viral load curve in treated infection. Fill indicates viral load area
under the curve in treated infection.
doi:10.1371/journal.pone.0158237.g005
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collected in volunteer challenge studies and possibly prospective cohort studies (for example
[22]).
The lower the measurement error and the higher the sensitivity of an assay, the more accu-
rate the data. Determining the distribution of the measurement error of a given assay can
improve statistical inference. This can be achieved by running replicate measurements at each
step of the assay on the same sample and from different samples taken from the same patient
at one time point. In the case of influenza A, the most common assays are RT-qPCR and
TCID50 [23,24]. Information on the error distribution of the assay can be incorporated in the
model fitting procedure to obtain more reliable estimates of infection-related quantities.
We suggest a number of laboratory experiments that could help to improve estimates of
model parameters and disease markers. Parameters that can be measured independently can
be set to a fixed value or allow the definition of better prior distributions during the model fit-
ting procedure, so that the remaining free parameters can be estimated with greater accuracy.
For example, the decay rate of influenza A virus has been measured previously in micro-car-
rier culture [25]. Viral culture medium, however, does not contain any components of the
immune system. Consequently, the measured viral decay rate is much lower than inside the
human host (provided he or she is not immunosuppressed). It should be possible to culture
virus and add serum taken at different times post infection from previously infected individuals
to the culture medium. This would give independent and more realistic estimates of the virus
decay rate in its natural environment.
The virus production rate per cell can be estimated by determining the total amount of virus
produced in a culture system and dividing it by the total amount of host cells in the system
[25]. The virus production rate may be affected by the innate immune response, as may be the
virus clearance rate. It would likely be viral strain- and cell type-specific and would have to be
measured for all strains against which a treatment was to be tested and for several respiratory
epithelial cell types. The half-life of cells infected by different strains can also be measured
using common apoptosis and cytotoxicity markers [26,27].
These experiments may not be cheap, and may be rather complex. In order to supplement
and validate data obtained from tissue culture systems, animal models may prove useful. In
particular, it may be possible to obtain data on the dynamics of infected cells from serial autop-
sies from sacrificed animals. The more components of the virus life cycle and the human
immune response can be measured independently the more complex and detailed models can
be built of viral infection. Hence better assessments of therapy impact can be made. Compared
to the cost of failed clinical trials, the cost and endeavour of additional laboratory experiments
should be worth the attempt.
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